Karyopharm Therapeutics Stock Price on December 3, 2024
| KPTI Stock | USD 0.74 0.01 0.99% |
Below is the normalized historical share price chart for Karyopharm Therapeutics extending back to November 06, 2013. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Karyopharm Therapeutics stands at 0.74, as last reported on the 11th of December 2024, with the highest price reaching 0.74 and the lowest price hitting 0.73 during the day.
If you're considering investing in Karyopharm Stock, it is important to understand the factors that can impact its price. Karyopharm Therapeutics is very risky at the moment. Karyopharm Therapeutics has Sharpe Ratio of 0.0189, which conveys that the firm had a 0.0189% return per unit of risk over the last 3 months. We have found thirty technical indicators for Karyopharm Therapeutics, which you can use to evaluate the volatility of the firm. Please verify Karyopharm Therapeutics' Mean Deviation of 3.1, risk adjusted performance of 0.022, and Downside Deviation of 4.09 to check out if the risk estimate we provide is consistent with the expected return of 0.0936%.
As of now, Karyopharm Therapeutics' Common Stock Shares Outstanding is increasing as compared to previous years. The Karyopharm Therapeutics' current Common Stock Total Equity is estimated to increase to about 14.5 K, while Total Stockholder Equity is forecasted to increase to (129.4 M). . The Karyopharm Therapeutics' current Price Earnings To Growth Ratio is estimated to increase to 0.02, while Price To Sales Ratio is projected to decrease to 0.64. Karyopharm Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of November 2013 | 200 Day MA 0.9874 | 50 Day MA 0.8472 | Beta 0.154 |
Karyopharm |
Sharpe Ratio = 0.0189
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | KPTI | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.95 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Karyopharm Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Karyopharm Therapeutics by adding it to a well-diversified portfolio.
Price Book 12.0484 | Enterprise Value Ebitda (1.85) | Price Sales 0.6163 | Shares Float 113.9 M | Wall Street Target Price 4.5 |
Related Headline
Valneva SE Headline on 3rd of December 2024
Valnevas Chikungunya Shot Shows Strong, Long-Lasting Antibod... by benzinga.com
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.
Karyopharm Therapeutics Valuation on December 3, 2024
It is possible to determine the worth of Karyopharm Therapeutics on a given historical date. On December 3, 2024 Karyopharm was worth 0.82 at the beginning of the trading date compared to the closed value of 0.81. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Karyopharm Therapeutics stock. Still, in general, we apply an absolute valuation method to find Karyopharm Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Karyopharm Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Karyopharm Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 0.84 | 0.84 | 0.82 | 0.83 | 315,155 | |
12/03/2024 | 0.82 | 0.86 | 0.80 | 0.81 | 1,018,878 |
| 0.81 | 0.82 | 0.78 | 0.79 | 1,504,054 |
| Backtest Karyopharm Therapeutics | | | Karyopharm Therapeutics History | | | Karyopharm Therapeutics Valuation | Previous | Next |
Karyopharm Therapeutics Trading Date Momentum on December 3, 2024
| On December 04 2024 Karyopharm Therapeutics was traded for 0.79 at the closing time. The top price for the day was 0.82 and the lowest listed price was 0.78 . The trading volume for the day was 1.5 M. The trading history from December 4, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 2.47% . The trading delta at closing time against the current closing price is 9.88% . |
Karyopharm Therapeutics Fundamentals Correlations and Trends
By evaluating Karyopharm Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Karyopharm financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Karyopharm Therapeutics Stock history
Karyopharm Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Karyopharm is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Karyopharm Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Karyopharm Therapeutics stock prices may prove useful in developing a viable investing in Karyopharm Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 114.2 M | 119.9 M | |
| Net Loss | -148.8 M | -156.2 M |
Karyopharm Therapeutics Quarterly Net Working Capital |
|
Karyopharm Therapeutics Stock Technical Analysis
Karyopharm Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Karyopharm Therapeutics Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Karyopharm Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Karyopharm Therapeutics December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Karyopharm Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Karyopharm Therapeutics shares will generate the highest return on investment. By undertsting and applying Karyopharm Therapeutics stock market strength indicators, traders can identify Karyopharm Therapeutics entry and exit signals to maximize returns
Karyopharm Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Karyopharm Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Karyopharm Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Karyopharm to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.022 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.69) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0877 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |